SEC Form 4 · accession 0001209191-19-019141
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey T. Walsh
Officer — Chief Strategy Officer
Period of report
Mar 11, 2019
Accepted (ET)
Mar 13, 2019 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 11, 2019 | M | 1,500 | $24.47 | A | 42,421 | D | |
| Common StockF2 | Mar 11, 2019 | S | 1,500 | $139.7988 | D | 40,921 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $24.47 | Mar 11, 2019 | M | 1,500 | D | — | Mar 3, 2024 | Common Stock | 1,500 | 14,521 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
- F2The range of prices for the transaction reported on this line was $139.30 to $140.05. The average weighted price was $139.7988. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.